01Billing team must audit active patient medication lists in the EHR/billing system to identify any patients currently on the 60+ excluded medications (e.g., Januvia, Entresto, Saxenda, Revlimid, Xeljanz, Harvoni, Epclusa, Sovaldi, OxyContin, Avanafil, Captopril, Cimetidine, Horizant, Ketoprofen, and others listed).
02For each affected medication, verify whether the patient is mid-treatment (applies to Harvoni, Epclusa, Sovaldi—which allow continuation) or requires immediate switching.
03Update billing software to flag claims containing excluded medications and automatically require generic/alternative substitution codes.
04Add Gemtesa step therapy requirement: system must validate that patients have failed at least two of the listed anticholinergics (darifenacin ER, fesoterodine ER, oxybutynin IR/ER, solifenacin, tolterodine IR/ER, trospium IR/ER, mirabegron) before approving coverage.
05Implement quantity limits in billing system: diabetic test strips (100/month without insulin, 300/month with insulin), Omnipod (10 pods/month), PEG-based bowel prep (2 kits/year), Twist refill kits (1/month).
06Notify providers of Viread removal from HCR list and update encounter templates to inform patients of increased cost-share effective January 1, 2027.
07Prepare denial/appeal response templates for claims submitted on or after January 1, 2027 containing excluded medications.
08Claims will be denied automatically unless prior authorization for alternatives is obtained in advance.